Finoriq research workspace
Eikon Therapeutics, Inc. (EIKN) News
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. Review EIKN recent headlines, source links, and company news on Finoriq.
Company Snapshot
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
- Company
- Eikon Therapeutics, Inc. (EIKN)
- Ticker
- EIKN
- Market Cap
- $526.2M
- Latest Price
- $9.72
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.